Literature DB >> 29102331

Vitamin D (25-OHD) deficiency may increase the prevalence of medication-related osteonecrosis of the jaw.

Nils Heim1, Felix Benjamin Warwas2, Christian Timm Wilms3, Rudolf H Reich4, Markus Martini5.   

Abstract

INTRODUCTION: Osteonecrosis of the jaw (ONJ) is a severe complication of antiresorptive medication (AM) in the treatment of bone-affecting cancer-related conditions and osteoporosis. Aim of this study was to reveal whether patients treated with AM and show Medication Related OsteoNecrosis of the Jaw (MRONJ) are vitamin D deficient or not.
MATERIALS AND METHODS: A 2 year retrospective study evaluated hospital records of 63 patients who received AM. Patients were divided into two groups. One group (n = 45) consisted of patients who presented a stage 2 ONJ (eb+ = exposed bone). Second group patients (n = 18) (eb- = no exposed bone) presented for extraction of teeth. Serum levels of vitamin D (25-OHD) were analysed. P values ≤ 0.05 in t-test were regarded as statistically significant.
RESULTS: Serum levels of 25-OHD were significantly higher in the eb(-) group (29.5 ng/ml), than in the eb(+) group (20.49 ng/ml). Blood levels of calcium were also significantly higher in eb(-) group (2.25 mmol/L; 0.11 SD) than in eb(+) group (2.175 mmol/L; 0.16 SD).
CONCLUSION: Prevalence of MRONJ in AM treated patients seems to be increased by low serum 25-OHD. A measurable tendency in the role of 25-OHD for the development of MRONJ was recorded and leads to the recommendation for a sufficient vitamin D substitution in patients treated with AM.
Copyright © 2017 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  25-OHD; BRONJ; MRONJ; Osteonecrosis; Vitamin D

Mesh:

Substances:

Year:  2017        PMID: 29102331     DOI: 10.1016/j.jcms.2017.09.015

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  10 in total

1.  Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study.

Authors:  Ana Laura Soares; Sérgio Simon; Luiz Henrique Gebrim; Afonso Celso P Nazário; Marise Lazaretti-Castro
Journal:  Support Care Cancer       Date:  2019-08-29       Impact factor: 3.603

2.  Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study.

Authors:  Masanori Nashi; Toshinori Hirai; Takuya Iwamoto; Toshihiko Takenobu
Journal:  J Bone Miner Metab       Date:  2022-09-27       Impact factor: 2.976

3.  Volumetric analysis of MRONJ lesions by semiautomatic segmentation of CBCT images.

Authors:  Matthias Zirk; Johannes Buller; Joachim E Zöller; Carola Heneweer; Norbert Kübler; Max-Philipp Lentzen
Journal:  Oral Maxillofac Surg       Date:  2019-10-31

4.  Antiresorptive drug-related changes of the mandibular bone densitiy in medication-related osteonecrosis of the jaw patients.

Authors:  Nils Heim; Werner Götz; Franz-Josef Kramer; Anton Faron
Journal:  Dentomaxillofac Radiol       Date:  2019-09-17       Impact factor: 2.419

Review 5.  Newly-identified Pathways Relating Vitamin D to Carcinogenesis: A Review.

Authors:  Nadeem Bilani; Leah Elson; Charles Szuchan; Elizabeth Elimimian; Mustafa Saleh; Zeina Nahleh
Journal:  In Vivo       Date:  2021-04-28       Impact factor: 2.406

Review 6.  Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Authors:  Athanasios D Anastasilakis; Jessica Pepe; Nicola Napoli; Andrea Palermo; Christos Magopoulos; Aliya A Khan; M Carola Zillikens; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

Review 7.  Vitamin D Deficiency and Oral Health: A Comprehensive Review.

Authors:  João Botelho; Vanessa Machado; Luís Proença; Ana Sintra Delgado; José João Mendes
Journal:  Nutrients       Date:  2020-05-19       Impact factor: 5.717

Review 8.  Medication-Related Osteonecrosis of the Jaw (MRONJ): Are Antiresorptive Drugs the Main Culprits or Only Accomplices? The Triggering Role of Vitamin D Deficiency.

Authors:  Luca Dalle Carbonare; Monica Mottes; Maria Teresa Valenti
Journal:  Nutrients       Date:  2021-02-08       Impact factor: 5.717

Review 9.  Schemes for Drug-Induced Treatment of Osteonecrosis of Jaws with Particular Emphasis on the Influence of Vitamin D on Therapeutic Effects.

Authors:  Filip Michalak; Sylwia Hnitecka; Marzena Dominiak; Kinga Grzech-Leśniak
Journal:  Pharmaceutics       Date:  2021-03-08       Impact factor: 6.321

10.  Bone turnover markers can predict healing time in medication-related osteonecrosis of the jaw.

Authors:  Lorenz Schubert; Guenter Russmueller; Heimo Lagler; Selma Tobudic; Elisabeth Heindel; Michael Kundi; Christoph Steininger
Journal:  Support Care Cancer       Date:  2021-06-30       Impact factor: 3.603

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.